Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SANOFI DEVELOPPEMENT PHARMA : revenue, balance sheet and financial ratios

SANOFI DEVELOPPEMENT PHARMA is a French company founded 30 years ago, specialized in the sector Activités des sociétés holding. Based in GENTILLY (94250), this company of category GE shows in 2024 a net income negative of -2.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SANOFI DEVELOPPEMENT PHARMA (SIREN 401393624)
Indicator 2024 2023
Revenue N/C N/C
Net income -2 224 000 € 5 137 000 €
EBITDA -39 000 € -695 000 €
Net margin N/C N/C

Revenue and income statement

In 2024, SANOFI DEVELOPPEMENT PHARMA records a net loss of 2.2 M€. This deficit will reduce equity on the balance sheet.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-39 000 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

60 000 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-2 224 000 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 22%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 81%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

22.092%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

81.058%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-384.2

Solvency indicators evolution
SANOFI DEVELOPPEMENT PHARMA

Sector positioning

Debt ratio
22.09 2024
2023
2024
Q1: 0.01
Med: 8.77
Q3: 62.6
Average +31 pts over 2 years

In 2024, the debt ratio of SANOFI DEVELOPPEMENT PHARMA (22.09) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
81.06% 2024
2023
2024
Q1: 15.71%
Med: 62.26%
Q3: 91.3%
Good -9 pts over 2 years

In 2024, the financial autonomy of SANOFI DEVELOPPEMENT PHARMA (81.1%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Repayment capacity
-384.2 years 2024
2023
2024
Q1: 0.0 years
Med: 0.09 years
Q3: 3.07 years
Excellent -25 pts over 2 years

In 2024, the repayment capacity of SANOFI DEVELOPPEMENT PHARMA (-384.20) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 0.00. Alert: short-term debt exceeds current assets. Risk of payment difficulties without cash reinforcement.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

0.0

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

-5748.718

Liquidity indicators evolution
SANOFI DEVELOPPEMENT PHARMA

Sector positioning

Liquidity ratio
0.0 2024
2023
2024
Q1: 138.65
Med: 681.09
Q3: 3914.52
Watch

In 2024, the liquidity ratio of SANOFI DEVELOPPEMENT PHARMA (0.00) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.

Interest coverage
-5748.72x 2024
2023
2024
Q1: -74.77x
Med: 0.0x
Q3: 0.0x
Average -9 pts over 2 years

In 2024, the interest coverage of SANOFI DEVELOPPEMENT PHARMA (-5748.7x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Positioning of SANOFI DEVELOPPEMENT PHARMA in its sector

Comparison with sector Activités des sociétés holding

Similar companies (Activités des sociétés holding)

Compare SANOFI DEVELOPPEMENT PHARMA with other companies in the same sector:

Voir toutes les statistiques du secteur Activités des sociétés holding

Frequently asked questions about SANOFI DEVELOPPEMENT PHARMA

What is the revenue of SANOFI DEVELOPPEMENT PHARMA ?

The revenue of SANOFI DEVELOPPEMENT PHARMA is not publicly disclosed (confidential accounts filed with INPI).

Is SANOFI DEVELOPPEMENT PHARMA profitable?

SANOFI DEVELOPPEMENT PHARMA recorded a net loss in 2024.

Where is the headquarters of SANOFI DEVELOPPEMENT PHARMA ?

The headquarters of SANOFI DEVELOPPEMENT PHARMA is located in GENTILLY (94250), in the department Val-de-Marne.

Where to find the tax return of SANOFI DEVELOPPEMENT PHARMA ?

The tax return of SANOFI DEVELOPPEMENT PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SANOFI DEVELOPPEMENT PHARMA operate?

SANOFI DEVELOPPEMENT PHARMA operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.